Recruiting New Mothers with Postpartum Depression for the Skylark Study

In 2019,  brexanolone was introduced by Sage Therapeutics as Zulresso, a novel treatment for postpartum depression.  The oral version of this novel antidepressant – SAGE 217 or zuranolone – is now finishing up its Phase [...]